Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.01.2013 | original article

Ginkgo biloba extract EGb 761® in the treatment of dementia: a pharmacoeconomic analysis of the Austrian setting

verfasst von: PD Dr. Michael Rainer, Hermann Mucke, Sandra Schlaefke

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2013

Einloggen, um Zugang zu erhalten

Excerpt

EGb 761® is a dry extract from Ginkgo biloba leaves (drug-extract ratio 35–67:1; extraction solvent: acetone 60 % (w/w)) which is adjusted to 22.0–27.0 % ginkgo flavonoids calculated as ginkgo flavone glycosides and 5.0–7.0 % terpene lactones consisting of 2.8–3.4 % ginkgolides A, B, C and 2.6–3.2 % bilobalide and contains less than 5 ppm ginkgolic acids [1]. Drug products based on EGb 761® have been approved in several countries, including Austria, for the symptomatic treatment of progressive mental impairment in dementia syndromes, where they are to be used as a component of a general therapeutic concept to address Alzheimer’s disease, vascular dementia, and mixed type dementia. …
Vorheriger Artikel Quality of life in patients with depression, panic syndrome, other anxiety syndrome, alcoholism and chronic somatic diseases: a longitudinal study in Slovenian primary care patients
Nächster Artikel Can the efficiency of modified Alvarado scoring system in the diagnosis acute appendicitis be increased with tenesmus?
Literatur
1.
Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol. 1992;34(4):352–8.PubMedCrossRef
2.
Hörr R, Kieser M. Pharmaco-economic evaluation of Ginkgo special extract EGb 761® for dementias in Austria. Wien Med Wochenschr. 2002;152(15–16):427–31 (in German).PubMedCrossRef
3.
Haan J, Hörr R. Delay in progression of dependency and need of care of dementia patients treated with Ginkgo special extract EGb 761®. Wien Med Wochenschr. 2004;154(21–22):511–4 (in German).PubMedCrossRef
4.
Napryeyenko O, Borzenko I, GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57(1):4–11.PubMed
5.
Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, et al. on behalf of the GOTADAY Study Group. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011;26(11):1186–94.
6.
Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46(3):713–23.
7.
Institute for Quality and Efficiency in Health Care (IQWiG). Ginkgo in Alzheimer’s disease. Executive summary. IQWiG reports—Commission no. A05-19B. Version 1.0; Status: 29.09.2008.
8.
Bracco L, Gallato R, Grigoletto F, et al. Factors affecting course and survival in Alzheimer’s disease. A 9-year longitudinal study. Arch Neurol. 1994;51(12):1213–9.PubMedCrossRef
9.
Heyman A, Peterson B, Fillenbaum G, Pieper C. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer’s disease. Neurology. 1996;46(3):656–60PubMedCrossRef
10.
11.
12.
Mega MS, Masterman DM, O’Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol. 1999;56(11):1388–93.PubMedCrossRef
13.
Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl. 2):S22–32.PubMedCrossRef
14.
Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593. doi: 10.1002/14651858.CD005593.
15.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH, on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. Section 12.5.4.3. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0, updated March 2011. The Cochrane Collaboration. 2011. www.cochrane-handbook.org/. Accessed 1 Aug 2011.
16.
Cates CJ. Simpson’s paradox and calculation of number needed to treat from metaanalysis. BMC Med Res Methodol. 2002;2:1.PubMedCrossRef
17.
18.
Scripnikov A, Khomenko A, Napryeyenko O, GINDEM-NP Study Group. Effects of Ginkgo biloba extract EGb 761® on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157(13–14):295–300.PubMedCrossRef
19.
Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat. 2011;7:209–15.PubMed
20.
Nacu A, Hörr R, Herrschaft H. Neuropsychiatric symptoms of dementia and related caregiver distress: effect of treatment by a once-daily formulation of Ginkgo biloba extract EGb 761®. Alzheimer’s & Dementia. 2011;7(4 Suppl. 1):S785.CrossRef
21.
Gilley DW, Bienias JL, Wilson RS, et al. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer’s disease. Psychol Med. 2004;34(6):1129–35.PubMedCrossRef
22.
de Vugt ME, Stevens F, Aalten P, et al. A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. Int Psychogeriatr. 2005;17(4):577–89.PubMedCrossRef
23.
Metadaten
Titel
Ginkgo biloba extract EGb 761® in the treatment of dementia: a pharmacoeconomic analysis of the Austrian setting
verfasst von
PD Dr. Michael Rainer
Hermann Mucke
Sandra Schlaefke
Publikationsdatum
01.01.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0307-x

Weitere Artikel der Ausgabe 1-2/2013

Festabend: 175 Jahre Gesellschaft der Ärzte in Wien

  • mitteilungen der gesellschaft der ärzte in wien

Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia

  • case report

Can the efficiency of modified Alvarado scoring system in the diagnosis acute appendicitis be increased with tenesmus?

  • original article

Quality of life in patients with depression, panic syndrome, other anxiety syndrome, alcoholism and chronic somatic diseases: a longitudinal study in Slovenian primary care patients

  • original article

Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. A letter to the authors

  • letter to the editor

The usefulness of ulcer size and location in the differential diagnosis of benign and malignant gastric ulcer

  • original article